This individual is a late-onset, mildly affected FRDA patient, who carries relatively short GAA repeat expansions and has higher baseline frataxin levels than the other patients, suggesting that HDAC inhibition may be more effective when long GAA repeat strongly downregulate FXN expression. The gene discussed is FXN; the disease is Friedreich ataxia.